A Phase 2 interventional study of Topical SM04554 solution and Topical SM04554 solution in Androgenetic Alopecia, sponsored by Biosplice Therapeutics, Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Biosplice Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 89th largest by enrollment of the 204 interventional ones that give a count, is one of 9 that started in 2015, is one of 48 in phase 2, and was the 53rd registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is close to the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Biosplice Therapeutics, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Biosplice Therapeutics, Inc. has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical SM04554 0.15% solution, once daily for approximately 90 days
Drug: Topical SM04554 solution
Topical SM04554 0.25% solution, once daily for approximately 90 days
Drug: Topical SM04554 solution
Topical vehicle solution, once daily for approximately 90 days
Drug: Topical vehicle solution
Study medication application will be performed by the individual subject at approximately the same time each day.
Study medication application will be performed by the individual subject at approximately the same time each day.
Vehicle solution application will be performed by the individual subject at approximately the same time each day.
Change From Baseline/Day 91 in Number of Terminal Hair Follicles (Terminal Anagen + Terminal Catagen and Telogen Follicles)
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Change From Baseline/Day 91 in Number of Terminal Anagen Hair Follicles
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Change From Baseline/Day 91 in Number of Terminal Catagen and Telogen Hair Follicles
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Change From Baseline/Day 91 in Number of Miniaturized Hair Follicles (Indeterminate + Vellus Follicles)
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Change From Baseline/Day 91 in Number of Indeterminate Hair Follicles
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Change From Baseline/Day 91 in Number of Vellus Hair Follicles
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Terminal and Miniaturized Hair Follicle Density/mm²
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Ratio of Terminal to Miniaturized Hair Follicles
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Beta-catenin in Epidermis and Infundibulum
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Ki-67 in Epidermis and Infundibulum
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
Ki-67 in Hair Bulb
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
Time frame: Day 91 and Day 135
| Milestone | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Started | 16 | 14 | 19 |
| Completed | 12 | 11 | 17 |
| Not completed | 4 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Prohibited medication | 1 | 0 | 0 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -1.6 ± 3.8 | -0.3 ± 7.2 | -1.7 ± 4.1 |
| Day 135 - Change from Baseline | -2.1 ± 8.0 | -2.7 ± 6.0 | -3.5 ± 3.9 |
| Day 135 - Change from Day 91 | -1.4 ± 5.0 | -0.1 ± 4.3 | -1.9 ± 4.1 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -1.1 ± 3.3 | 1.3 ± 5.4 | -1.1 ± 3.7 |
| Day 135 - Change from Baseline | -2.4 ± 4.1 | -0.9 ± 2.7 | -1.9 ± 3.5 |
| Day 135 - Change from Day 91 | -1.5 ± 2.3 | -0.6 ± 3.7 | -0.9 ± 3.1 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -0.5 ± 2.8 | -1.6 ± 3.4 | -0.6 ± 2.3 |
| Day 135 - Change from Baseline | 0.3 ± 5.7 | -1.9 ± 4.6 | -1.6 ± 1.9 |
| Day 135 - Change from Day 91 | 0.1 ± 5.2 | 0.4 ± 1.6 | -1.0 ± 2.0 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -1.8 ± 18.3 | 0.3 ± 19.0 | -5.0 ± 11.5 |
| Day 135 - Change from Baseline | 4.1 ± 13.1 | 1.4 ± 5.3 | -2.8 ± 7.7 |
| Day 135 - Change from Day 91 | 8.0 ± 18.7 | -3.9 ± 19.2 | 4.4 ± 14.0 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -0.4 ± 5.1 | 3.1 ± 5.5 | 0.1 ± 5.3 |
| Day 135 - Change from Baseline | 1.4 ± 4.3 | 1.1 ± 4.3 | 0.2 ± 3.6 |
| Day 135 - Change from Day 91 | 1.5 ± 5.1 | -1.9 ± 4.1 | -1.3 ± 5.3 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Hair Count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 (Primary) - Change from Baseline | -1.5 ± 16.3 | -2.8 ± 16.0 | -5.1 ± 11.2 |
| Day 135 - Change from Baseline | 2.8 ± 12.7 | 0.3 ± 5.6 | -3.0 ± 7.8 |
| Day 135 - Change from Day 91 | 6.5 ± 14.4 | -2.0 ± 15.4 | 5.7 ± 11.0 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| number of follicles per square mm | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 - Change from Baseline | -0.3 ± 1.6 | -0.0 ± 1.2 | -0.5 ± 1.0 |
| Day 135 - Change from Baseline | 0.2 ± 1.2 | -0.1 ± 0.7 | -0.5 ± 0.6 |
| Day 135 - Change from Day 91 | 0.5 ± 1.2 | -0.3 ± 1.3 | 0.2 ± 1.1 |
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| ratio | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 - Change from Baseline | 0.40 ± 1.10 | 0.04 ± 0.33 | -0.17 ± 0.43 |
| Day 135 - Change from Baseline | -0.02 ± 0.28 | -0.08 ± 0.19 | -0.06 ± 0.62 |
| Day 135 - Change from Day 91 | -0.80 ± 1.24 | -0.05 ± 0.26 | 0.13 ± 0.70 |
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| percentage of nuclei stained positive | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 - Change from Baseline | 1.7 ± 2.3 | -0.9 ± 2.8 | -0.3 ± 2.1 |
| Day 135 - Change from Baseline | 1.5 ± 2.5 | -1.0 ± 3.1 | 1.2 ± 2.9 |
| Day 135 - Change from Day 91 | -0.3 ± 0.5 | 0.4 ± 0.5 | 1.1 ± 1.6 |
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Percent of cells that stain positive | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 - Change from Baseline | 13.2 ± 9.0 | 13.1 ± 19.2 | 11.1 ± 16.1 |
| Day 135 - Change from Baseline | 5.8 ± 9.2 | 6.3 ± 12.0 | 8.8 ± 16.4 |
| Day 135 - Change from Day 91 | -7.6 ± 10.1 | -8.5 ± 17.3 | 0.0 ± 15.4 |
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.
| Percent of cells that stain positive | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 91 - Change from Baseline | 4.9 ± 21.7 | 3.2 ± 19.1 | -11.7 ± 21.6 |
| Day 135 - Change from Baseline | -7.5 ± 26.9 | 10.8 ± 19.2 | -15.6 ± 29.2 |
| Day 135 - Change from Day 91 | -1.9 ± 13.3 | -3.0 ± 9.0 | -6.6 ± 26.8 |
Collected over Treatment-emergent AEs reporting start with the subject's first exposure to study medication at Day 1 through Day 135 (End of Study) or early termination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SM04554 0.15% | 0/16 (0%) | 0/16 (0%) | 9/16 (56.3%) |
| SM04554 0.25% | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Vehicle | 0/19 (0%) | 0/19 (0%) | 11/19 (57.9%) |
| Event | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Application site pruritusGeneral disorders and administration site conditions | 2/16 | 1/14 | 2/19 |
| ContusionInjury, poisoning and procedural complications | 2/16 | 0/14 | 0/19 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 2/16 | 0/14 | 1/19 |
| Upper respiratory tract infectionInfections and infestations | 1/16 | 1/14 | 2/19 |
| Pain of skinSkin and subcutaneous tissue disorders | 0/16 | 0/14 | 2/19 |
| ConstipationGastrointestinal disorders | 0/16 | 1/14 | 0/19 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 1/14 | 1/19 |
| Application site paraesthesiaGeneral disorders and administration site conditions | 0/16 | 1/14 | 1/19 |
| NasopharyngitisInfections and infestations | 1/16 | 1/14 | 0/19 |
| PneumoniaInfections and infestations | 0/16 | 1/14 | 0/19 |
| Age, Continuous(years) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 49.5 ± 11.8 | 48.2 ± 11.2 | 50.5 ± 9.3 | 49.5 ± 10.5 |
| Sex: Female, Male(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 16 | 14 | 19 | 49 |
| Ethnicity (NIH/OMB)(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 15 | 14 | 19 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 7 | 15 |
| White | 12 | 10 | 12 | 34 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| United States | 16 | 14 | 19 | 49 |
| Weight [kg](kg) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 105.2 ± 30.0 | 93.2 ± 23.8 | 89.8 ± 16.2 | 95.8 ± 24.0 |
| Height [cm](cm) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 178.0 ± 5.2 | 177.3 ± 6.3 | 176.9 ± 6.9 | 177.4 ± 6.1 |
| Body Mass Index [kg/m²](kg/m²) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 33.1 ± 8.9 | 29.5 ± 6.6 | 28.7 ± 5.1 | 30.4 ± 7.1 |
1 further baseline measures are reported on the registry.
The record gives a start of Aug 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2026, 10 years 6 months after primary completion. A results delay was requested in Jul 2018.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalosirvat
Biosplice Therapeutics, Inc. →